Trial Profile
Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid beta Antibody in Patients With Alzheimer's Disease.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 23 Dec 2021
Price :
$35
*
At a glance
- Drugs Solanezumab (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Registrational
- Acronyms EXPEDITION-EXT
- Sponsors Eli Lilly and Company
- 18 Dec 2021 This trial has been completed in Italy, according to European Clinical Trials Database record. (17 Feb-2017)
- 29 Mar 2017 This trial has been completed in Spain (End date:2017-02-17) as per European Clinical Trials Database record.
- 07 Mar 2017 Status changed from active, no longer recruiting to discontinued.